

**CFI (light chain) Blocking Peptide (C-term)**  
**Synthetic peptide**  
**Catalog # BP21688b****Specification**

---

**CFI (light chain) Blocking Peptide (C-term) - Product Information**Primary Accession [P05156](#)**CFI (light chain) Blocking Peptide (C-term) - Additional Information**

Gene ID 3426

**Other Names**

Complement factor I, C3B/C4B inactivator, Complement factor I heavy chain, Complement factor I light chain, CFI, IF

**Target/Specificity**

The synthetic peptide sequence is selected from aa 467-482 of HUMAN CFI

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**CFI (light chain) Blocking Peptide (C-term) - Protein Information**

Name CFI

Synonyms IF

**Function**

Trypsin-like serine protease that plays an essential role in regulating the immune response by controlling all complement pathways. Inhibits these pathways by cleaving three peptide bonds in the alpha- chain of C3b and two bonds in the alpha-chain of C4b thereby inactivating these proteins (PubMed:<a href="http://www.uniprot.org/citations/7360115" target="\_blank">7360115</a>, PubMed:<a href="http://www.uniprot.org/citations/17320177" target="\_blank">17320177</a>). Essential cofactors for these reactions include factor H and C4BP in the fluid phase and membrane cofactor protein/CD46 and CR1 on cell surfaces (PubMed:<a href="http://www.uniprot.org/citations/2141838" target="\_blank">2141838</a>, PubMed:<a href="http://www.uniprot.org/citations/9605165" target="\_blank">9605165</a>, PubMed:<a href="http://www.uniprot.org/citations/12055245" target="\_blank">12055245</a>). The presence of these cofactors on healthy cells allows degradation of deposited C3b by CFI in order to prevent undesired complement activation, while in apoptotic cells or microbes, the

absence of such cofactors leads to C3b-mediated complement activation and subsequent opsonization (PubMed:<a href="http://www.uniprot.org/citations/28671664" target="\_blank">28671664</a>).

**Cellular Location**

Secreted, extracellular space. Secreted

**Tissue Location**

Expressed in the liver by hepatocytes (PubMed:6327681). Also present in other cells such as monocytes, fibroblasts or keratinocytes (PubMed:6444659, PubMed:17320177)

**CFI (light chain) Blocking Peptide (C-term) - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

**CFI (light chain) Blocking Peptide (C-term) - Images****CFI (light chain) Blocking Peptide (C-term) - Background**

Responsible for cleaving the alpha-chains of C4b and C3b in the presence of the cofactors C4-binding protein and factor H respectively.

**CFI (light chain) Blocking Peptide (C-term) - References**

Catterall C.F.,et al.Biochem. J. 242:849-856(1987).  
Goldberger G.,et al.J. Biol. Chem. 262:10065-10071(1987).  
Hillier L.W.,et al.Nature 434:724-731(2005).  
Minta J.O.,et al.Gene 208:17-24(1998).  
Ullman C.G.,et al.FEBS Lett. 371:199-203(1995).